IFNB1 and relapsing-remitting multiple sclerosis: One may therefore hypothesize that the absence of release of HGF in the serum may be associated with the capacity of blood monocytes from IFN–β–treated RRMS patients to release mature bioactive HGF directly in specific targets, such as patients’ damaged CNS.